TME PHARM.CONF.IPO EO 1- (F:0N6A) — Market Cap & Net Worth
Market Cap & Net Worth: TME PHARM.CONF.IPO EO 1- (0N6A)
TME PHARM.CONF.IPO EO 1- (F:0N6A) has a market capitalization of $10.44 Million (€8.93 Million) as of September 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #27049 globally and #2313 in its home market, demonstrating a -4.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TME PHARM.CONF.IPO EO 1-'s stock price €0.11 by its total outstanding shares 94888981 (94.89 Million). Also see total assets of TME PHARM.CONF.IPO EO 1- for a full breakdown of the balance sheet.
TME PHARM.CONF.IPO EO 1- Market Cap History: 2018 to 2026
TME PHARM.CONF.IPO EO 1-'s market capitalization history from 2018 to 2026. Data shows change from $10.74 Billion to $12.71 Million (-61.60% CAGR). Also see 0N6A cash flow metrics for how efficiently the company converts equity into cash flow.
TME PHARM.CONF.IPO EO 1- Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TME PHARM.CONF.IPO EO 1-'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 0N6A stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0N6A by Market Capitalization
Companies near TME PHARM.CONF.IPO EO 1- in the global market cap rankings as of September 19, 2026. Review TME PHARM.CONF.IPO EO 1- tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to TME PHARM.CONF.IPO EO 1- by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
TME PHARM.CONF.IPO EO 1- Historical Marketcap From 2018 to 2026
Between 2018 and today, TME PHARM.CONF.IPO EO 1-'s market cap moved from $10.74 Billion to $ 12.71 Million, with a yearly change of -61.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €12.71 Million | +81.90% |
| 2025 | €6.99 Million | -8.30% |
| 2024 | €7.62 Million | -70.13% |
| 2023 | €25.52 Million | -80.83% |
| 2022 | €133.12 Million | -94.47% |
| 2021 | €2.41 Billion | -66.67% |
| 2020 | €7.22 Billion | +10.34% |
| 2019 | €6.55 Billion | -39.05% |
| 2018 | €10.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of TME PHARM.CONF.IPO EO 1- was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.44 Million USD |
| MoneyControl | $10.44 Million USD |
| MarketWatch | $10.44 Million USD |
| marketcap.company | $10.44 Million USD |
| Reuters | $10.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About TME PHARM.CONF.IPO EO 1-
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indicatio… Read more